Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novartis Takes All Of Ofatumumab
by Rick Mullin
August 31, 2015
| A version of this story appeared in
Volume 93, Issue 34
Novartis has acquired the remaining rights to ofatumumab, a monoclonal antibody under development for the treatment of multiple sclerosis and other autoimmune diseases, from GlaxoSmithKline. Novartis previously acquired the rights to ofatumumab for oncology and currently markets it under the name Arzerra. Under the new deal, Novartis will pay GSK $300 million up front and $200 million more following the start of Phase III trials in multiple sclerosis. GSK is eligible for an additional $534 million in milestone payments as well as royalties on commercialized drugs.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X